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Stopping the cuts
The recently discovered enzymes that process the
precursors of inflammatory cytokines are good targets for
the design of new anti-inflammatory therapeutic agents.
Cytokines such as interleukin-1 (IL-1) and tumor necro-
sis factor (TNF) are potent inflammatory mediators
when administered to animals or humans. If the produc-
tion or action of these cytokines could effectively be
blocked, it might be of immense clinical benefit as a way
of ameliorating inflammation. Blocking the ability of
IL-1 or TNF to trigger their respective receptors has had
some success as an anti-inflammatory strategy. For ex-
ample, treating humans with the natural IL-1 receptor
antagonist (IL-lRa) [1] or with neutralizing antibodies to
TNF [2] has reduced signs and symptoms of rheumatoid
arthritis. Blocking IL-1 [3,4] or TNF [5] has also amelior-
ated the severity and even lethality of some human dis-
eases. The results of these human trials are consistent
with hundreds of reports demonstrating that blocking
IL-1 or TNF action leads to a reduction of disease in ani-
mal models of lethal infection, severe inflammation or
autoimmune-mediated processes.
The clinical use of IL-lRa, soluble IL-1 receptors, anti-
bodies to TNF or soluble TNF receptors is, however,
limited by the need to deliver such proteins by injection.
This reduces the potential usefulness of these agents in
the treatment of many chronic inflammatory diseases,
and in less severe situations, such as acute but non life-
threatening trauma. The development of orally active
drugs to reduce the production of IL-1 and/or TNF thus
remains a highly desirable goal. Although cyclooxygenase
inhibitors and corticosteroids are anti-inflammatory
drugs par excellence, the side effects of their chronic use
are often unacceptable.
IL-1 and TNF are made from precursor proteins (Fig. 1),
and studies of their production - particularly of the sub-
types IL-I1 and TNFot - have established that synthesis
of the precursors and release of the mature cytokines into
the extracellular compartment are distinct events. IL-113
is unusual in that the precursor lacks a leader sequence, is
barely active and remains in the cytosol until cleavage
and release. TNFo has a weak leader sequence, seems to
be associated with the Golgi apparatus and exists in a
membrane-bound form before being cleaved and
released [6]. The precursors for IL-1 3 [7] and TNFct [8]
undergo myristoylation on lysines, which is thought to
contribute to their membrane localization.
Although the amino-terminal sequences of the extra-
cellular forms of IL-1P and TNFao have been known for
several years, how these forms .are cleaved from their
precursors and transported out of the cell was, until
recently, poorly understood. Clearly, IL-1 and TNF can-
not have any systemic effects unless they are released
from the cells in which they are produced. A major
breakthrough came three years ago, with the discovery
of IL-1P converting enzyme (ICE) [9,10]. This discov-
ery immediately set in motion a search for specific
inhibitors of ICE which, like inhibitors of angiotensin
converting enzyme (ACE), should provide specific and
safe therapeutic agents.
ICE is a constitutively produced, intracellular cysteine
protease, which seems to be the sole enzyme for cleaving
precursor IL-1P at the site - between aspartic acid resi-
due 116 and alanine residue 117 - that releases the
mature form of IL-1f. ICE is stored in cells in an inac-
tive form, but becomes enzymatically active when the
cells are exposed to the same stimuli that induce the syn-
thesis of IL-1. Substrate-based inhibitors of ICE have
been used to prevent cleavage of the 31kD IL-113 pre-
cursor, and thus release of the 17kD mature IL-13, in
human blood and animal monocytes [11]. Inhibition of
ICE has also been shown to lead to a reduction in
inflammatory disease.
The results of three recent studies [12-14] imply that
there are also specific proteases which cleave the 26kD
TNFot precursor, releasing the 17 kD mature form of
TNFa. Unlike ICE, the sequence of the putative TNFao
converting enzyme (TACE) is presently unknown, but it
seems to be in the general class of zinc-binding metallo-
proteinases [12,14]. In vitro, metalloproteinase inhibitors
and zinc chelators suppress the processing of TNFot from
human blood monocytes and murine macrophages, but
do not affect the release of lymphotoxin-ot from T lym-
phocytes or the release of other cytokines [12-14]. These
metalloproteinase inhibitors did not affect production of
IL-13 or IL-6 in whole human blood incubated with
lipopolysaccharide (LPS) [14]; even membrane-associated
cytokines, such as macrophage colony stimulating factor
(M-CSF) and transforming growth factor o (TGFa),
were unaffected. The proteinase inhibitors used in these
studies are not specific, as they can inhibit the cleavage of
other proteins. However, when administered to rats or
mice, the proteinase inhibitors reduced circulating levels
of TNFu induced by LPS [13,14]. Moreover, pretreat-
ment of mice with one of the processing inhibitors
reduced the sensitivity of the mice to the lethal effect of
LPS (which can be almost 100% when LPS is given after
galactosamine, which damages the liver and increases
sensitivity to LPS) [13].
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Of considerable importance to the use of both present
and future inhibitors of ICE and TACE is the observa-
tion that, when these proteases are inhibited, there is a
build up in the levels of their respective precursors in or
on the surface of cells. In the case of IL-1, there is an
increase in the amount of IL-I1 precursor that is found
in the extracellular compartment [10]; in the case of
TNFa, there is an increase in the membrane-associated
form of this cytokine [13]. Does inhibition of these pro-
teases only delay the processing event until new enzyme
is synthesized or the levels of the inhibitors fall? Would
rapid processing and cleavage of the precursors occur at a
later time and aggravate inflammation? Probably not. For
IL-1p, precursor molecules are released from cells during
inhibition of ICE and it seems they are not cleaved extra-
cellularly by elastase or similar enzymes present in whole
blood or inflammatory exudates. This is, in part, because
the IL-13 precursor binds tightly to the constitutively
produced, soluble type II IL-1 receptor, which probably
prevents its haphazard cleavage [15-18].
Unlike the IL-13 precursor, the precursor for TNFot is
not usually found in the extracellular space. It seems that
intracellular levels of the TNFot precursor, which are
increased as precursor processing is inhibited, decrease
with time; the excess cytokine precursor molecules, are
thought to be degraded intracellularly [13]. Cell death
and the release of intracellular cytokine precursor mol-
ecules do take place in inflammatory fluids - such as
synovial fluid from arthritis patients or peritoneal fluid
from peritonitis patients - but the two common en-
zymes to which the released precursors are exposed in
the extracellular compartment, elastase and cathepsin G,
degrade the TNFot precursor into biologically inactive
fragments [19].
Other examples of cell-associated cytokines requiring a
proteolytic cleavage step for their maturation include
M-CSF, TGFao and endothelin-1. Of relevance to
inflammation, the precursor of IL-l1( is vulnerable to
cleavage by a calcium-dependent, membrane-associated
serine protease (calpain) [20,21]. Unlike TNFao and
IL-13, however, IL-la is primarily an intracellular mol-
ecule, and precursor IL-la is active as a membrane-
bound form, requiring cell-cell contact for biological
activity [22]. Processing and release of IL-l requires
special circumstances - the activation of calpain by a
calcium ionophore, or stimulation of cells with very large
numbers of bacteria. Ordinarily, LPS or cytokine stimu-
lation of human monocytes is accompanied by the spon-
taneous release of IL-13 and TNFxa, but not of IL-lat
[23-25]. Nevertheless, evaluating IL-lot release in exper-
imental models employing serine protease inhibitors may
help interpretation of the data, particularly as these
inhibitors are non-specific.
Do these cytokine-cleaving proteases play a critical role in
the progression of inflammation and disease? The recent
generation of ICE-deficient mice by targeted gene
inactivation [26,27] sheds new light on this question. The
Fig. 1. Proteolytic processing of IL-1Ig, IL-la and TNFa. The
31 kD precursor for IL-1I (pro-IL-1i ) is initially translated and
found in the cytosol; it is transported to the vicinity of the cell
membrane, where it is cleaved by the intracellular IL-1 con-
verting enzyme (ICE), generating the mature (17 kD) form, which
is secreted into the extracellular space. ICE must be activated
before it can cleave pro-IL-1 P. Precursor IL-I a (pro-lL-1 a) is also
found in the cytosol; it is myristoylated and inserted into the cell
membrane, where it is cleaved by the membrane-associated,
calcium-activated protease calpain, generating mature (17kD)
IL-la, which is secreted into the extracellular space. The precur-
sor for TNFa is also myristoylated and found in the cell mem-
brane, where it seems to be cleaved by a zinc-dependent
metalloproteinase (TNFa converting enzyme, TACE; see text),
releasing mature (1 7 kD) TNFa.
ICE-deficient mice show a prolonged survival following a
lethal challenge with endotoxin [26], suggesting that
cleavage of precursor IL-1l by ICE plays a role in sys-
temic inflammation. Macrophages from these mice do
not secrete IL-1; unexpectedly, they also do not secrete
IL-lot, despite the presence of large amounts of intracel-
lular IL-loa [26,27]. It has been speculated that ICE par-
ticipates in the activation of the calpains that cleave
precursor IL-la. Further studies of ICE-deficient mice
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should clarify the role of ICE in models of local inflam-
mation and autoimmune diseases.
The effects of inhibiting ICE may not be entirely
straightforward, however, as the ICE gene belongs to the
family of'cell-death' genes, such as ced-3 [28] and Nedd-2
[29]. The products of these genes, and other members of
the ICE family, share a pentapeptide sequence that is
required for ICE activity. Transfection of cells with a
gene encoding a member of the ICE gene family
increases their chances of undergoing programmed cell
death (or apoptosis) [30,31]. So, will any ICE-specific
inhibitors considered for use in clinical medicine have
side effects due to a reduction in apoptosis? This is an
important question, as the proper functioning of the
immune system requires apoptosis. Furthermore, many
malignant cells undergo apoptosis, so it is possible that a
treatment that reduces apoptosis would increase the risk
of malignant disease.
If inhibition of ICE reduces natural apoptotic mecha-
nisms, then one would expect that, as a result, there
would be an increase in the survival or proliferation of
cells that would otherwise undergo apoptosis. However,
experiments have shown that specific inhibition of ICE
in human peripheral blood mononuclear cells or cultured
leukemic cell lines does not reduce endotoxin-induced
apoptosis (our unpublished observations). Furthermore,
specific inhibition of ICE does not increase the proL
liferation of malignant cells from patients with acute
myelogenous leukemia [32,33]. And the two recent stud-
ies of ICE-deficient mice [26,27] show that their thymo-
cytes and macrophages undergo normal apoptosis when
stimulated by corticosteroids or irradiation.
One study [27], however, has found that cells from ICE-
deficient mice are resistant to the apoptosis that is nor-
mally induced by treatment with antibodies against the
cell-surface protein Fas, a member of the TNF receptor
family that is thought to act as an 'apoptosis receptor'.
Fas-induced apoptosis seems to involve the binding of a
novel protein called MORT 1 to the intracellular domain
of Fas [34], and this binding may depend upon a proteo-
lytic-cleavage step. MORT 1 is an intracellular protein
that could be another substrate for ICE. As thymocytes
from ICE-deficient mice are resistant to Fas-induced
apoptosis [27], the failure to cleave MORT 1 in ICE-
deficient cells may explain these results. Cleavage of a
MORT 1 precursor may also explain why transfected
cells expressing elevated ICE levels undergo higher rates
of apoptosis.
Nonetheless, ICE-deficient mice have normal thymuses.
The overall impression is that specific inhibition of ICE
activity is not associated with defects in apoptosis under
most conditions, and it seems unlikely that drugs which
inhibit cleavage of the IL-1 precursor will result in run-
away growth of cancer cells or prevent lymphocyte apop-
tosis during immune responses. Blocking the release of
IL-1P or TNFot by inhibiting their respective processing
enzymes thus remains a potentially important approach
to the treatment of inflammation. The expectation is that
inhibitors of ICE or TNF'-processing enzymes will
enter clinical medicine, as have inhibitors of ACE and
the human immunodeficiency virus-1 (HIV-1) protease.
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